P&G is working with advisers to review up to 100 underperforming brands for potential divestiture.» Read More
A contrarian investment strategy known as "Dogs of the Dow" has been a laggard this year, pulled down by Citigroup, one of the biggest casualties of the subprime credit meltdown.
The seven biggest stories in my sectors in 2007? Avandia, Dendreon, Pfizer, Biogen were just a few of the topics that made this a fascinating year for the pharmaceuticals and biotechnology industries.
Strong gains in consumer spending and technology stocks fueled a long-awaited Santa Claus rally on Wall Street.
Shares of biotech behemoth Amgen are trading at a new intra-day low in the early going this morning after the company announced new data on its developmental osteoporosis drug late Friday. The Phase 3, or late-stage, study was designed to see if the twice-a-year injectable drug strengthened the bones of women with a certain type of breast cancer.
The morning after the Merck annual business briefing, the analyst reviews are pouring in. For the most part, the ones that I've received at least, say it had a good beat. Only Sanford C. Bernstein's Tim Anderson says he can't dance to it. He titles a research note to clients, "Annual Business Review Uneventful--No Real Surprises, Positive Or Negative."
Today's Fed decision just made recession more likely, Cramer says.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
I'm back at Merck HQ in central Jersey for the annual analyst meeting. And I must say that the reception--so far, at least--is much more hospitable and helpful than last year wen things were tense and got a little ugly. A new pr team is in place.
Merck Tuesday reaffirmed its earnings forecast and said it plans to begin late-stage trials next year on a drug to raise "good" HDL cholesterol that has not been dogged by the problems that sank a similar high-profile drug being developed by Pfizer.
How aggressive will the Fed be? They are expected to cut 25 basis points and many are expecting a 50 basis point cut in the discount rate. Some are also expecting new innovations to encourage banks to use the discount window.
Earlier this week I blogged about Amgen's negative test results for its anemia drug Aranesp in breast cancer. The studies showed the drug may have caused tumors to grow and death. This morning it almost seems like there's a delayed market reaction.
I don't know how they all got clustered together--maybe so many of the major pharmaceutical companies meet with Wall Street in early December so everyone can then take off on long vacations--but my hands are full with three big pharma events in as many days. Yesterday, Merck put out guidance.
Merck gave profit forecasts for 2007 and 2008 that were mostly below expectations.
Shares of Dow component Merck are trading lower in the very early going this morning after the country's second-biggest drug company didn't blow people away with its 2008 financial guidance. Merck puts out its new forecast a week ahead of its annual analyst meeting, so it can focus more on its drug development pipeline at the event.
Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Futures lower this morning on pressure from the financials. The UBS headline for the bank analyst report this morning tells the story: lower earnings ahead. They are adjusting their 2008 earnings expectations for many banks and brokers.
Shares of Addex Pharmaceuticals SA jumped Monday after the Swiss company said it entered a license agreement with U.S.-based Merck to develop a new class of orally available drugs to treat Parkinson's disease and perhaps other conditions.
Regarding my post from yesterday about Lilly CEO Sidney Taurel, a spokesman left me a voicemail this morning to say it has no intention of backing out of the interview next week. I've got a tentative commitment from Bristol-Myers Squibb to interview its new CEO Jim Cornelius for the first time at that company's analyst meeting next week.
During regular trading hours on Tuesday, Merck shares hit 60 bucks. If you bought the stock about two years ago and held it, you've doubled your money. Merck traded for 45 bucks and change the day before the company recalled Vioxx. It hadn't been above 60 since mid-2003. This has to go down as one of the greatest comeback stories in history.
If you eat it, drink it or smoke it - then buy it.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
So, does this mean I'm gonna get scooped by Reuters on Merck stories? I'm just kidding, but that was one of my reactions when I saw the press release this morning from Merck announcing that it's putting the CEO of Reuters, Tom Glocer, on its Board of Directors. The head of a financial data and news company on the Board of a major drug company. Very interesting.